Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer
NCT00268476Phase 3Active, not recruiting
- Sponsor
- Medical Research Council
- Start
- Jul 2005
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of zoledronic acid, docetaxel, celecoxib, abiraterone, enzalutamide in prostate cancer (PCa), sponsored by Medical Research Council. Started Jul 2005; status: active, not recruiting.
02
Drugs
zoledronic aciddocetaxelcelecoxibabirateroneenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00268476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268476.